Business Context and Reporting Period
This Form 8-K was filed by ReShape Lifesciences Inc. (RSLS) on April 7, 2023. The report addresses a material restatement of financial statements for the year ended December 31, 2021, and unaudited quarterly periods from June 30, 2021, through September 30, 2022. The filing discloses that previously issued financial statements are no longer reliable due to accounting errors identified during the preparation of the 2022 annual report.
Key Financial Metrics
The filing does not provide updated revenue, profit, cash flow, or liquidity figures. The primary financial disclosure relates to a specific accounting error:
- Asset Reclassification: A $1.9 million Directors' and Officers' (D&O) Tail Policy, previously capitalized as an acquired asset from the June 2021 merger with Obalon Therapeutics Inc., was determined to be a non-cash error.
- Correction: The policy should have been expensed in full on the effective date of the merger rather than capitalized.
- Other Errors: The company identified immaterial errors regarding stock option fair value calculations (Q3 2021), reserves for uncertain tax positions, and valuation allowances related to asset impairments.
Material Changes and Restatement Details
The Board of Directors, based on management recommendations and consultation with independent auditors RSM US LLP, determined that the financial statements for the 2021 fiscal year and subsequent quarters were materially misstated. The core issue was the improper capitalization of the D&O Tail Policy. Additionally, the company filed a Form 12b-25 on April 3, 2023, requesting a 15-day extension to file its 2022 Form 10-K, with a new target date of April 17, 2023, though no assurance is given that this deadline will be met.
Outlook, Risks, and Internal Controls
Internal Control Deficiencies: Management concluded that internal controls over financial reporting were ineffective as of June 30, 2021, through December 31, 2022. This ineffectiveness is attributed to insufficient internal resources with appropriate accounting and finance expertise to design and operate effective controls.
Risks and Contingencies:
- There is no assurance that additional material weaknesses will not be identified during the completion of the 2022 Form 10-K.
- The timing of the restatement completion remains uncertain.
- Forward-looking statements regarding the restatement process are subject to risks and uncertainties that could cause actual results to differ materially.
Investor Verification Checklist
- Verify the filing status and expected completion date of the restated 2022 Form 10-K.
- Monitor for the issuance of restated financial statements for the 2021 fiscal year and the affected quarterly periods.
- Assess the impact of the $1.9 million expense reclassification on historical net income and asset balances.
- Review future filings for updates on the remediation of internal control weaknesses and the hiring of additional accounting resources.
- Confirm whether the company has met the April 17, 2023, deadline for the 2022 Form 10-K or if further extensions are required.